H.C. Wainwright initiated coverage of OKYO Pharma with a Buy rating and $4 price target. OKYO is a clinical stage biopharmaceutical company focused on the development of novel therapeutics for inflammatory eye diseases and ocular pain, the analyst tells investors in a research note. If the Phase 2 trial meets both sign and symptom endpoints, it would be a major de-risking event for OK-101, says the firm.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on OKYO:
- OKYO Pharma announces $5.84M cash raise
- OKYO Pharma Announces Filing of an Investigational New Drug (IND) Application for OK-101 to Treat Neuropathic Corneal Pain (“NCP”)
- OKYO Pharma files IND application for OK-101 in NCP
- OKYO Pharma announces safety data profile for OK-101 Phase 2 trial of DED
- OKYO Pharma Announces Closing of $4.0 Million Registered Direct Offering of Ordinary Shares
